Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 20 clinical trials
featured
Advanced and Recurrent Endometrial Cancer (DUO-E)

People with cancer are asked to participate in a research study being conducted by Icahn School of Medicine at Mount Sinai.

  • 22 views
  • 22 Jul, 2020
  • 1 location
Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

This is a phase 2 study of investigational drug niraparib and TSR-042 in patients with advanced/recurrent endometrial cancer. The purpose of this study is to determine whether blocking a protein

PTEN
carcinosarcoma
recurrent endometrial cancer
cancer
measurable disease
  • 87 views
  • 22 Dec, 2019
  • 7 locations
Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

This study seeks to determine the effectiveness of Rucaparib as maintenance therapy for metastatic and recurrent endometrial cancer, after 1-2 prior lines of therapy.

  • 0 views
  • 29 Mar, 2020
  • 1 location
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

This is a a Simon's two-stage, non-randomized, open label, 2-arm Phase II trial of ONC201 in women with metastatic or recurrent Type II endometrial cancer who failed at least 1 prior chemotherapy regimen.

neutrophil count
metastatic disease
chemotherapy regimen
carcinosarcoma
measurable disease
  • 48 views
  • 17 Sep, 2020
  • 3 locations
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

patients with newly diagnosed advanced or recurrent endometrial cancer.

durvalumab
endometrial carcinoma
carcinoma
carcinosarcoma
measurable disease
  • 104 views
  • 31 Dec, 2020
  • 166 locations
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune …

neutrophil count
step 2
carcinoma
replacement therapy
recurrent endometrial cancer
  • 71 views
  • 17 Jan, 2021
  • 116 locations
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)

The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is

endometrial carcinoma
carcinoma
recurrent endometrial cancer
mk-3475
hormone therapy
  • 403 views
  • 19 Jan, 2021
  • 213 locations
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

participants with advanced or recurrent endometrial cancer. Participants with primary stage IV or recurrent disease who are in partial or complete response after having completed a single line of at least 12

neutrophil count
carcinosarcoma
recurrent endometrial cancer
cancer
platelet count
  • 47 views
  • 20 Jul, 2020
  • 57 locations
Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer

The DOMEC trial is designed as a Dutch Gynecological Oncology Group (DGOG), prospective, multi-center, phase II study for 55 patients with advanced (recurrent, refractory or metastatic) endometrial cancer or carcinosarcoma of the uterus to investigate the efficacy of the combination therapy of olaparib tablets and durvalumab IV.

durvalumab
neutrophil count
metastatic disease
recurrent endometrial cancer
platelet count
  • 9 views
  • 14 Jul, 2019
  • 5 locations
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer

The purpose of this study is to determine the effectiveness of the combination of abemaciclib and fulvestrant in treating this type of cancer and to determine the types and severity of side effects caused by treatment with abemaciclib and fulvestrant.

progesterone
neutrophil count
endometrial carcinoma
chemotherapy regimen
recurrent endometrial cancer
  • 17 views
  • 19 Dec, 2020
  • 8 locations